Dr. Shore on US launch of PSMA PET imaging agent piflufolastat F 18 for prostate cancer
Neal D. Shore, MD, discusses the US commercial launch of the PSMA PET imaging agent piflufolastat F 18 (Pylarify). Lantheus, the developer of piflufolastat F 18, selected oncology provider GenesisCare to administer the first commercially available dose of the agent.
Piflufolastat F 18 was approved by the FDA in May 2021 based on findings from the CONDOR and OSPREY studies. In the CONDOR study, 63.9% of men with biochemically recurrent prostate cancer who had no evidence of disease on standard-of-care imaging had a change in intended management after their piflufolastat F 18 scan.
Shore is US chief medical officer of Surgery and Urology, GenesisCare, and medical director of the Carolina Urologic Research Center.
GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial
February 11th 2022For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.
